European Society for Medical Oncology
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
Sandoz partners with Samsung Bioepis to develop up to five biosimilars
The agreement will expand the pipeline and builds on an existing partnership
Sandoz appoints Armin Metzger as President of new global unit
Metzger was most recently Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals
Sandoz launches first and only multiple sclerosis biosimilar in US
The treatment is FDA-approved to treat MS and Crohn’s disease
Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities
Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti
The biosimilars have been authorised for all indications covered by Amgen's reference medicines
Sandoz separates from Novartis as an independent spin-off company
The split allows Sandoz to strengthen its position in generics and biosimilars
Sandoz biosimilar receives EC approval to treat MS
Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe
Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis
The disease-modifying therapy is approved to treat all indications covered by Tysabri
Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar
The neurological disease affects approximately 2.8 million people worldwide
Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US
Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease
Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership
The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates